speb/financial-data huggingface dataset:
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 90951000.00
CONCORDBIO.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 104634863.00
CONCORDBIO.NS income_statement (quarterly, 2024-09-30) — Basic EPS: 9.15
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 34236000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 74000000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 3182936000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 15903792000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 2486711000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 9346524000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 18169000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 18169000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1417126000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 38594000.00
CONCORDBIO.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 104634863.00
CONCORDBIO.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: 9.15
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 7836000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 8060326000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 2504245000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 15903792000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 90951000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 16067000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 16067000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 4545000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 15333000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 8060326000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 15895956000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 291130000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 214886000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 93516000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 15799176000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 102726000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 5573615000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 3108936000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Payables: 840872000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 15903792000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 15895956000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 17643448000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 15903792000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 34236000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 15903792000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1739656000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 8296924000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 322530000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 19157000.00
CONCORDBIO.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 7929398000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 1071342000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 2442202000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 104574518.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 7.26
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 523980000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 132640000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 132640000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 104574518.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 7.26
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — EBIT: 1012497000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — EBITDA: 1145137000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 1918222000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 974000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 974000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -974000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -974000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 1145137000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 759211000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Operating Income: 846880000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 2442202000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 147294000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 592297000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 1011523000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 523980000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 132640000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 252312000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.25
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 1595322000.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
CONCORDBIO.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — +Operating Expense: 3987653000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 1255802000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — +Total Revenue: 11798178000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 4298838000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 1130398000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 1130398000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 5216515000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 5216515000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -2886730000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -2886730000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -31751000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -31751000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Amortization: 3136000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 3136000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 220441000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 220441000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 104616204.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 104610432.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Basic EPS: 35.52
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 13.42
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 151421000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 3576123000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 3576123000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -1111722000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 25882000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 25882000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 9045000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 9045000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3346342000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 3346342000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -915392000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 9045000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 9045000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -317134000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -139404000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 216627000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Payable: 220891000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -1707877000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -1707576000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -142376000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -915392000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 18127175000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 18127175000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 575960000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 575960000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 3177056000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1284975000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Assets: 11352422000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 11352422000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 19584000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 19584000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Debt: 3811000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 3811000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 23395000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 23395000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 1840626000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1840626000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 55400000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 55400000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Depreciation: 540599000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 543735000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 543735000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 146166000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 540599000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 146166000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 104616204.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 104610432.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Diluted EPS: 35.52
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 13.42
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1403872000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 526000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 526000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — EBIT: 4950826000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — EBIT: 1836397000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — EBITDA: 5494561000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — EBITDA: 1982563000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — End Cash Position: 9045000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 179890000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 179890000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -987680000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 210346000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 210346000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 1333447000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -222637000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 2247000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 128861000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Goodwill: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 11221000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 11221000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 5248266000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 5248266000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 11403583000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 11403583000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Gross Profit: 8621122000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 3013863000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 3578000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 3578000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Interest Expense: 5293000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 955000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 5293000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 955000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Interest Income: 17101000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 17101000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -6332000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 29946000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Inventory: 2396672000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 2396672000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 18130986000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 18130986000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -1599865000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 220441000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 220441000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Investmentsin Joint Venturesat Cost: 7365000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Investmentsin Joint Venturesat Cost: 7365000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 629929000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 629929000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 6298000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 6298000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 6298000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 6298000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -58487000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 7365000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 7365000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 28199000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 28199000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 5953634000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 5953634000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 0.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Net Debt: 3811000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 3811000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -12924000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income: 1403872000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1403872000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1403872000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1403872000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1403872000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 4945533000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 3716423000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1403872000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Interest Income: 6684000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -955000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -446908000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -58487000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -58487000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 6684000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -955000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: 1497000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: -73171000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Net PPE: 8516853000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 8516853000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -1109732000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 18115954000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 18115954000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 340217000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 340217000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 28199000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 28199000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 79084000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 79084000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 5274162000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 1982563000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Normalized Income: 3550799615.67
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 1403872000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 2445169000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Operating Income: 4633469000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Operating Income: 1758061000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Operating Revenue: 11798178000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 4298838000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 153637000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 153637000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 113186000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 113186000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 18022559000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 18022559000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 11221000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 11221000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Inventories: 7884000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 7884000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -12763000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 126007000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 126007000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 16218000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 93840000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 1749380000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 719979000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Payable: 444592000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 444592000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Properties: 667937000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 667937000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 142433000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 142433000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 3346342000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 3346342000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Other Special Charges: 2238000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Payables: 1676784000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Payables: 1676784000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 169466000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 169466000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Pretax Income: 4945533000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 1835442000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: -9480000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -8699389000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -1111722000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 840141000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 840141000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 3177056000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1284975000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 543735000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 146166000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 110298000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 110298000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -58487000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 10394000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 10394000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 16910670000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 16910670000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 8252481000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 1990000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 345518000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 474379000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Special Income Charges: -2238000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 18127175000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 18127175000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 18115954000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 18115954000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 54775615.67
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Tax Provision: 1229110000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 431570000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.25
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.24
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 67022000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 67022000.00
CONCORDBIO.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -1094187000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Assets: 20342515000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 20342515000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 18127175000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 18127175000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Debt: 29693000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 29693000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 18127175000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 18127175000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Total Expenses: 7164709000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 2540777000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 2215340000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2215340000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 8990093000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 8990093000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 374714000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 374714000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 5124000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 101268000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 101268000.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 220399000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
CONCORDBIO.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 220399000.00
CONCORDBIO.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1338301000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1338301000.00
CONCORDBIO.NS balance_sheet (annual, 2025-03-31) — Working Capital: 9511796000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 9511796000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1152619000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 2039876000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 104650356.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 4.21
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 451042000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 177763000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 177763000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 104650356.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 4.21
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — EBIT: 587904000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — EBITDA: 765667000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 1588834000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 586000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 586000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -586000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -586000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 765667000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 440578000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Operating Income: 436215000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 2039876000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 136776000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 595882000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 587318000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 451042000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 177763000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 146740000.00
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.25
CONCORDBIO.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1603661000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 1279416000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 2470575000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 865848000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 3967889000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 458070000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 104581758.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 6.03
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 16066000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 172880000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 3813930000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 18274622000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 741728000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 490163000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 10798414000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 10415000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 10415000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1549820000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 55695000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 183915000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 183915000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 104581758.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 6.03
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — EBIT: 857431000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — EBITDA: 1041346000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 3963000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 19776000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 8622690000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 1980412000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 591000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 591000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 2762773000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 18274622000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 458070000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 5651000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 5651000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 45201000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 24580000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: -6518000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -591000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -591000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 8622690000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 18254846000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 384030000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 1041346000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 630628000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Operating Income: 700996000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 2470575000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 253822000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 180560000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 18170006000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 15813000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 109041000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 1000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 133521000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 650946000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 7880962000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 3641050000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Payables: 870246000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 856840000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 490163000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 183915000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 18274622000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 18254846000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 226212000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.26
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 20232186000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 18274622000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 16066000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 18268104000.00
CONCORDBIO.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 1769579000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 1964082000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 9433772000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 414262000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 4398000.00
CONCORDBIO.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 9248594000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 1317977000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 2777660000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 104673520.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 6.08
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 657348000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 187469000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 187469000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 104673520.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 6.08
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — EBIT: 862374000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — EBITDA: 1049843000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 2120312000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 815000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 815000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 636415000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -815000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -815000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 1082597000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 660609671.42
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Operating Income: 802335000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 2777660000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 99762000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 662701000.00